Previous 10 | Next 10 |
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While never entirely out of fashion, penny stocks are drawing new-found attention from retail investors. One reason for this interest is that many new traders see the penny stock market as a way of turning a small investm...
NEWARK, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple presentations of resu...
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q2 2021 Earnings Call Transcript...
CymaBay Therapeutics, Inc. (CBAY) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - Chief Executive Officer Dennis Kim - Chief Medical Officer Chuck McWherter - Chief Scientific Officer Conference Call Participa...
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trial Active...
NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
CymaBay Therapeutics (NASDAQ:CBAY) announced a $100M non-dilutive financing from Abingworth aimed at the Phase 3 development of liver disease drug seladelpar. The funding will be earmarked for Phase 3 program of seladelpar in primary biliary cholangitis (PBC) including the Phase 3 RESPON...
Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biop...
New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on develop...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...